Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > respiratory syncytial virus therapeutics market
Get a free sample of Respiratory Syncytial Virus Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Respiratory Syncytial Virus Therapeutics Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The respiratory syncytial virus therapeutics industry is characterized by the presence of several key players offering innovative products. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their service portfolios, and gain a competitive advantage.
Prominent players operating in the industry include:
Market size for respiratory syncytial virus therapeutics was USD 5.8 billion in 2023 and is expected to register 12.8% CAGR from 2024-2032 owing to the ongoing advancements in treatment, rising disease burden, growing aging population, and increased early childhood healthcare worldwide.
Respiratory syncytial virus therapeutics industry from the palivizumab segment recorded USD 3.3 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its high efficacy in preventing severe RSV infections in high-risk populations.
North America industry is expected to register 12.7% CAGR from 2024-2032 due to the presence of advanced healthcare infrastructure, including well-equipped hospitals, healthcare facilities, and research institutions in the region.
AbbVie Inc., AstraZeneca PLC, Bausch Health Companies Inc., Gilead Sciences, GSK plc, Johnson & Johnson, Medivir AB, Merck & Co., Inc, Pfizer Inc., and Sanofi, are some of the major respiratory syncytial virus therapeutics companies worldwide.